PIII-57Pharmacokinetics and dopamine D2 And serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: Two open-label, single-dose studies
The DOI matches its Crossref record.
Abstract
OBJECTIVES Assess pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone immediate-release 1mg (paliperidone IR; Study 1) and paliperidone extended-release tablets 6mg (paliperidone ER; Study 2). METHODS Blood samples were collected pre-dose and ≤24h (Study 1) and ≤48h (Study 2). Striatal D2 receptor binding was measured using PET and 11C-raclopride pre-dose and post-dose at 2.5h (Study 1) and at 22h and 46h (predicted Cmax; Study 2). Frontal cortex 5-HT2A receptor occupancy (Study 1) was assessed using[11C]M100,907 ≥1 week pre-dose and 4.5h post-dose (Cmax). The apparent dissociation constant (KDapp=plasma concentration at which 50% of target receptor is occupied) was estimated using an Emax model. RESULTS Formulation differences were reflected in tmax and Cmax. Paliperidone ER 6mg corresponds to median D2 occupancy of 64% at 22h post-dose. Using the KDapp, plasma concentrations corresponding to 70–80% D2 occupancy were estimated: 15–25ng/mL (Study 1); 10–17ng/mL (Study 2). Using pooled data from both studies the in vivo KDapp is estimated to be 4.9ng/mL. CONCLUSION Paliperidone occupies central D2 and 5HT2A receptors. D2 receptor occupancy with paliperidone ER suggests 6mg will be an effective dose in the treatment of schizophrenia. (See Table) Measure Paliperidone IR 1mg*. Study 1 (n=3) Paliperidone ER 6mg*. Study 2 (n=4) Median Cmax (ng/mL) (range) 6.02 (5.34–6.14) 11.3 (7.73–16.5) Median tmax (h) (range) 4.2 (4.1–8.1) 24.1 (23.1–29.0) Median % D2 receptor occupancy (range) 48 (35–51)[2.5h post-dose] 64 (56–79)[22h post-dose]; 53 (40–62)[46h post-dose] Calculated KDapp for D2-receptor occupancy (ng/mL) 6.4 4.4 Median % 5-HT2A-receptor occupancy (range) 65 (65–71)[4.5h post-dose] Not measured Corresponding plasma concentration range (mg/mL) 5.1–6.0[4.0h post-dose] Not measured a Initial studies have shown that paliperidone ER has a bioavailability of approximately 33% of that of paliperidone IR. Clinical Pharmacology & Therapeutics (2005) 79, P74–P74; doi: 10.1016/j.clpt.2005.12.265
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
KANE, J., CANAS, F., KRAMER, M., FORD, L., GASSMANNMAYER, C., LIM, P., & EERDEKENS, M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.09.012 · Cited by 296
Self-citationCoppola, D., Liu, Y., Gopal, S., Remmerie, B., Samtani, M. N., Hough, D. W., Nuamah, I., Sulaiman, A., & Pandina, G. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-26 · Cited by 61
“…the majority of patients had plasma concentrations above 7.5 ng/mL (Figure 3), the minimum required plasma paliperidone concentration associated with a central D2-receptor occupancy of approximately 60% (Karlsson et al., 2006) that is generally considered the threshold for antipsychotic efficacy.”
BackgroundInfluentialSchoretsanitis, G., Spina, E., Hiemke, C., & de Leon, J. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1549489 · Cited by 50
Berwaerts, J., Cleton, A., Rossenu, S., Talluri, K., Remmerie, B., Janssens, L., Boom, S., Kramer, M., & Eerdekens, M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106914 · Cited by 49
Self-citationCleton, A., Rossenu, S., Crauwels, H., Berwaerts, J., Hough, D., Gopal, S., Eerdekens, M., Vandebosch, A., Remmerie, B., De Meulder, M., et al. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.295 · Cited by 48
Self-citation
Metadata
- Authors
- KARLSSON, P., DENCKER, E., NYBERG, S., MANNAERT, E., BOOM, S., TALLURI, K., ROSSENU, S., ERIKSSON, B., EERDEKENS, M., & FARDE, L.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2006-02
- Volume
- 79
- Issue
- 2
- Pages
- P74-P74
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2315045824
- Cited by
- 37
- References
- 0
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PIII-57Pharmacokinetics and dopamine D2 And serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: Two open-label, single-dose studies. https://app.cochat.ai/papers/10.1016/j.clpt.2005.12.265
- The paper
- KARLSSON, P., DENCKER, E., NYBERG, S., MANNAERT, E., BOOM, S., TALLURI, K., ROSSENU, S., ERIKSSON, B., EERDEKENS, M., & FARDE, L. (2006). PIII-57Pharmacokinetics and dopamine D2 And serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: Two open-label, single-dose studies. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/j.clpt.2005.12.265
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.